Home » Acorda Therapeutics Has Investigational New Drug Application Accepted
Acorda Therapeutics Has Investigational New Drug Application Accepted
Acorda Therapeutics, Inc. Tuesday announced plans to initiate a Phase 1 single-dose clinical trial of the Company’s compound, Glial Growth Factor
2, in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration on March 19, 2010.
MarketWatch
MarketWatch
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May